Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended ImmTAC candidate in patients with tumors that express PRAME
| IMCR Stock | USD 30.23 0.59 1.91% |
Slightly above 62% of Immunocore Holdings' investor base is looking to short. The analysis of the overall investor sentiment regarding Immunocore Holdings suggests that many traders are alarmed. Immunocore Holdings' investing sentiment overview a quick insight into current market opportunities from investing in Immunocore Holdings. Many technical investors use Immunocore Holdings stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Immunocore |
Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended ImmTAC candidate in patients with tumors that express PRAME IMC-P115C targets the same peptide and has the same CD3 effector and TCR specificity as brenetafusp, and is designed with extended half-life The Phase 1 trial will assess the safety and clinical activity of IMC-P115C in HLA-A0201-positive patients with advanced solid tumors that express PRAME OXFORDSHIRE, England C
Read at finance.yahoo.com
 |
Immunocore Holdings Fundamental Analysis
We analyze Immunocore Holdings' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immunocore Holdings using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immunocore Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Book Value Per Share
Book Value Per Share Comparative Analysis
Immunocore Holdings is currently under evaluation in book value per share category among its peers. Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
Immunocore Holdings Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Immunocore Holdings stock to make a market-neutral strategy. Peer analysis of Immunocore Holdings could also be used in its relative valuation, which is a method of valuing Immunocore Holdings by comparing valuation metrics with similar companies.
Peers
Immunocore Holdings Related Equities
| ERAS | Erasca | 3.00 | ||||
| MIRM | Mirum Pharmaceuticals | 0.14 | ||||
| NUVL | Nuvalent | 2.33 | ||||
| LRMR | Larimar Therapeutics | 4.29 | ||||
| KALV | Kalvista Pharmaceuticals | 5.94 | ||||
| ACLX | Arcellx | 6.22 | ||||
| PCVX | Vaxcyte | 7.14 | ||||
| GLUE | Monte Rosa | 8.27 | ||||
| VRDN | Viridian Therapeutics | 8.42 | ||||
| LYRA | Lyra Therapeutics | 9.09 | ||||
| VTYX | Ventyx Biosciences | 10.71 | ||||
| DSGN | Design Therapeutics | 14.19 |
Additional Tools for Immunocore Stock Analysis
When running Immunocore Holdings' price analysis, check to measure Immunocore Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunocore Holdings is operating at the current time. Most of Immunocore Holdings' value examination focuses on studying past and present price action to predict the probability of Immunocore Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunocore Holdings' price. Additionally, you may evaluate how the addition of Immunocore Holdings to your portfolios can decrease your overall portfolio volatility.